Cancer Biology Platform

Cancer Biology
Platform

Early in our history, BeiGene developed a proprietary cancer biology platform that incorporates improved models and processes for drug discovery into the new world of immuno-oncology and combination approaches to cancer treatment. Our discovery engine addresses the importance of tumor-immune system interactions and the value of primary tumor biopsies in developing new cancer models.

Cancer Biology Platform

Understanding Cancer to Design Against It

Understanding Cancer to Design Against It

We have built an extensive collection of novel in vitro, ex vivo and in vivo cancer models, in order to better select targets and to screen and evaluate agents that may have significant potential alone or in combination. Our cancer models also integrate elements of the human immune system, allowing us to evaluate potential drug candidates in conditions that approximate a patient’s cancer at the time of treatment. This is particularly significant when drug discovery requires evaluation not only of monotherapies but also multiple combinations and regimens targeting specific mutations while simultaneously immobilizing the defenses cancer cells mount against the human immune system.

Molecularly Targeted Agents
Molecularly Targeted Agents

Utilizing rational drug design to identify and target the genes and proteins that drive cancer

Immuno-Oncology Therapies
Immuno-Oncology Therapies

Harnessing the human immune system in the tumor microenvironment

Combination Solutions
Combination Solutions

Combining immuno-oncology agents with targeted treatments; exploring key synergies

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

Accept